期刊文献+

双氢青蒿素对下咽癌Fadu细胞凋亡的影响 被引量:4

Effects of dihydroartemisinin on the apoptosis of Fadu cells
原文传递
导出
摘要 目的:探讨双氢青蒿素(DHA)对下咽癌Fadu细胞凋亡的影响。方法:用不同浓度DHA干预下咽癌Fadu细胞,观察DHA对细胞形态的影响;分别于24h或48h后用MTT法检测细胞增殖的变化并计算IC50值。用AnnexinⅤ-FITC凋亡检测试剂盒分析DHA对Fadu细胞凋亡的影响。用Western Blot法测定DHA对Bcl-2、Bcl-xl、Mcl-1、Bax和C-PARP凋亡相关基因的影响。结果:一定浓度的DHA可显著改变细胞的形态学变化,抑制下咽癌Fadu细胞增殖且明显增加凋亡细胞的数量,该变化与干预浓度和时间呈依赖关系。进一步研究结果提示,DHA可显著抑制Bcl-2、Bcl-xl和Mcl-1抗凋亡蛋白的表达,同时增加促凋亡蛋白Bax和C-PARP的表达。结论:DHA可显著抑制下咽鳞状细胞癌Fadu细胞的增殖,并明显增加细胞的凋亡,其机制与DHA调控Bcl-2家族密切相关。提示,Bcl-2家族成员在DHA抑制下咽鳞状细胞癌Fadu细胞增殖的过程中发挥了重要作用。 Objective:To investigate the effect of dihydroartemisinin (DHA) on the apoptosis of Fadu cells. Method:Fadu cells were treated with DMSO or different doses of DHA for 24 or 48 h. After that, IC50 values of DHA were calculated based on the cell viability tested via MTT assay, the cell morphology was observed,the percentage of apoptotic cells was analyzed with the Annexin V-FITC Apoptosis Detection Kit, and some important regulators of apoptosis,such as Bcl-2, Bcl-xl, Mcl-1, Bax, and C-PARP were determined by Western blotting. Result:Certain doses of DHA significantly inhibited the proliferation and induced apoptosis of Fadu cells in a dose time-dependent manners. DHA also downregulated the expression of antiapoptotic proteins (Bcl-2, Bcl-xl, and Mcl-1) and upregulated the expression of proapoptotic proteins(Bax and C-PARP). Conclusion: DHA remarkably inhibited proliferation and induction of apoptosis in Fadu cells via affecting proteins of Bcl-2 family. DHA may be a promising drug to treat hypopharyngeal carcinoma.
出处 《临床耳鼻咽喉头颈外科杂志》 CAS 北大核心 2016年第21期1685-1688,共4页 Journal of Clinical Otorhinolaryngology Head And Neck Surgery
基金 河北省应用基础研究计划重点基础研究项目
关键词 双氢青蒿素 下咽肿瘤 凋亡 BCL-2 dihydroartemisinin hypopharyngeal neoplasms apoptosis Bcl-2
  • 相关文献

参考文献18

  • 1MI Y J, GENG G J, ZOU Z Z, et al. Dihydroarte- misinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells[J]. PLoS One, 2015, 10: e0120426- e0120426.
  • 2LUCIBELLO M, ADANTI S, ANTELMI E, et al. Phospho-TCTP as a therapeutic target of Dihydroarte- misinin for aggressive breast cancer cells [J]. Onco- target, 2015, 6.5275-5291.
  • 3ZHANG C Z, ZHANG H, YUN J, et al. Dihydroar- temisinin exhibits antitumor activity toward hepatocel- lular carcinoma in vitro and in vivo [J]. Biochem Pharmacol, 2012, 83:1278-1289.
  • 4ZHAO X, ZHONG H, WANG R, et al. Dihydroar- temisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxa-mediated pathway re- quiring iron and endoperoxide moiety [J]. Oncotar- get, 2015, 6:5582-5596.
  • 5JIA G, KONG R, MA Z B, et al. The activation of c- Jun NH(2)-terminal kinase is required for dihydroar- temisinin-induced autophagy in pancreatic cancer cells [J]. J Exp Clin Cancer Res, 2014, 33.8-12.
  • 6ZHANG Z S, WANG J, SHEN Y B, et al. Dihydro- artemisinin increases temozolomide efficacy in glioma cells by inducing autophagy [J]. Oncol Lett, 2015,I0-379-383.
  • 7ZHAO C, GAO W, CHEN T. Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine [J]. Apoptosis, 2014,19 : 668- 681.
  • 8TAKES R P, STROJAN P, SILVER C E, et al. Current trends in initial management of hypopharyn- geal cancer: the declining use of open surgery [J]. Head Neck, 2012,34-270-281.
  • 9LIGIER K, BELOT A, LAUNOY G, et al. Descrip- tive epidemiology of upper aerodigestive tract cancers in France. incidence over 1980-2005 and projection to 2010 [J]. Oral Oncol, 2011,47:302-307.
  • 10PFISTER D G, ANG K K, BRIZEL D M, et al. Na- tional comprehensive cancer network clinical practice guidelines in oncology head and neck cancers [J]. J Natl Compr Canc Netw, 2011, 9:596-650.

二级参考文献13

  • 1曹培国,王肇炎.青蒿素及其衍生物的抗肿瘤作用[J].肿瘤防治杂志,2004,11(6):666-668. 被引量:15
  • 2CAPONIGRO F, LONGO F, IONNA F, et al.Treatment approaches to nasopharyngeal carcinoma :a review[J]. Anticancer Drugs,2010,21 :471 —477.
  • 3EFFERTH T, DUNSTAN H, SAUERBREY A, etal. The anti-malarial artesunate is also active againstcancer[J]. Int J Oncol,2001,18 : 767 — 773.
  • 4EFFERTH T. Molecular pharmacology andpharma-cogenomics of artemisinin and its derivatives in canc-er cells [J]. Curr Drug Targets, 2006 ,7 :407 — 421.
  • 5CHEN H,SUN B, PAN S, et al. Dihydroartemisinininhibits growth of pancreatic cancer cells in vitro andin vivo[J]. Anticancer Drugs, 2009,20: 131 — 140.
  • 6JIAO Y,GE C M, MENG Q H,et al. Dihydmarte-misinin is an inhibitor of ovarian cancer cell growth[J]. Acta Pharmaeol Sin,2007 ,28 : 1045 — 1056.
  • 7CHEN H,SUN B, WANG S,et al. Growth inhibi-tory effect's of dihydroartemisinin on pancreatic canc-er cells : involvement of cell cycle arrest and inactiva-tion of nuclear factor-kappaB[J]. J Cancer Res ClinOncol, 2010,136: 897 — 903.
  • 8MAO H, GU H, QU X, et al. Involvement of themitochondrial pathway and Bim/Bcl-2 balance in di-hydroartemisinin-induced apoptosis in human breastcancer in vitro[J]. Int J Mol Med,2013,31: 213 —218.
  • 9LU J, CHEN S M, ZHANG X W, et al. The anti cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells[J]. In vest New Drugs, 2011, 29.. 1276--1283.
  • 10ZHANG C Z, ZHANG H, YUN J, et al. Dihydroar temisinin exhibits antitumor activity toward hepatocel- lular carcinoma in vitro and in vivo[J]. Biochem Pharmacol. 2012, 83:1278 1289.

共引文献3

同被引文献14

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部